Name | Number of supported studies | Average coverage | |
---|---|---|---|
mast cell | 17 studies | 30% ± 14% | |
epithelial cell | 5 studies | 27% ± 10% | |
glutamatergic neuron | 4 studies | 29% ± 10% | |
GABAergic neuron | 3 studies | 26% ± 4% | |
basal cell | 3 studies | 23% ± 5% | |
neuron | 3 studies | 19% ± 3% | |
astrocyte | 3 studies | 20% ± 6% | |
oligodendrocyte precursor cell | 3 studies | 19% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 970.99 | 459 / 459 | 100% | 57.39 | 1118 / 1118 |
prostate | 100% | 855.92 | 245 / 245 | 100% | 39.40 | 501 / 502 |
esophagus | 100% | 1061.70 | 1442 / 1445 | 100% | 37.53 | 183 / 183 |
stomach | 100% | 745.05 | 358 / 359 | 100% | 30.84 | 286 / 286 |
uterus | 100% | 921.45 | 170 / 170 | 100% | 37.38 | 457 / 459 |
brain | 100% | 979.98 | 2629 / 2642 | 100% | 34.58 | 705 / 705 |
intestine | 100% | 1024.50 | 966 / 966 | 99% | 31.94 | 524 / 527 |
liver | 100% | 956.45 | 226 / 226 | 99% | 27.01 | 403 / 406 |
bladder | 100% | 950.10 | 21 / 21 | 99% | 31.58 | 500 / 504 |
thymus | 100% | 914.91 | 653 / 653 | 99% | 31.03 | 599 / 605 |
skin | 100% | 1875.58 | 1809 / 1809 | 97% | 31.05 | 458 / 472 |
lung | 97% | 757.61 | 561 / 578 | 100% | 29.88 | 1154 / 1155 |
kidney | 100% | 776.93 | 89 / 89 | 97% | 20.81 | 870 / 901 |
ovary | 99% | 730.77 | 179 / 180 | 96% | 18.02 | 411 / 430 |
pancreas | 94% | 447.61 | 309 / 328 | 99% | 27.57 | 176 / 178 |
adrenal gland | 100% | 1096.35 | 257 / 258 | 93% | 22.72 | 214 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 32.76 | 29 / 29 |
spleen | 100% | 975.65 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 35.80 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 10.87 | 1 / 1 |
adipose | 100% | 817.51 | 1202 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 668.99 | 1324 / 1335 | 0% | 0 | 0 / 0 |
muscle | 97% | 672.35 | 782 / 803 | 0% | 0 | 0 / 0 |
heart | 92% | 526.66 | 796 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 79% | 13.92 | 63 / 80 |
peripheral blood | 66% | 813.83 | 612 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001711 | Biological process | endodermal cell fate commitment |
GO_0031124 | Biological process | mRNA 3'-end processing |
GO_0045638 | Biological process | negative regulation of myeloid cell differentiation |
GO_0006368 | Biological process | transcription elongation by RNA polymerase II |
GO_0016055 | Biological process | Wnt signaling pathway |
GO_0019827 | Biological process | stem cell population maintenance |
GO_0032968 | Biological process | positive regulation of transcription elongation by RNA polymerase II |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005813 | Cellular component | centrosome |
GO_0016593 | Cellular component | Cdc73/Paf1 complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0001650 | Cellular component | fibrillar center |
GO_0005634 | Cellular component | nucleus |
GO_1990269 | Molecular function | RNA polymerase II C-terminal domain phosphoserine binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LEO1 |
Protein name | RNA polymerase-associated protein LEO1 (Replicative senescence down-regulated leo1-like protein) |
Synonyms | RDL |
Description | FUNCTION: Component of the PAF1 complex (PAF1C) which has multiple functions during transcription by RNA polymerase II and is implicated in regulation of development and maintenance of embryonic stem cell pluripotency. PAF1C associates with RNA polymerase II through interaction with POLR2A CTD non-phosphorylated and 'Ser-2'- and 'Ser-5'-phosphorylated forms and is involved in transcriptional elongation, acting both independently and synergistically with TCEA1 and in cooperation with the DSIF complex and HTATSF1. PAF1C is required for transcription of Hox and Wnt target genes. PAF1C is involved in hematopoiesis and stimulates transcriptional activity of KMT2A/MLL1; it promotes leukemogenesis through association with KMT2A/MLL1-rearranged oncoproteins, such as KMT2A/MLL1-MLLT3/AF9 and KMT2A/MLL1-MLLT1/ENL. PAF1C is involved in histone modifications such as ubiquitination of histone H2B and methylation on histone H3 'Lys-4' (H3K4me3). PAF1C recruits the RNF20/40 E3 ubiquitin-protein ligase complex and the E2 enzyme UBE2A or UBE2B to chromatin which mediate monoubiquitination of 'Lys-120' of histone H2B (H2BK120ub1); UB2A/B-mediated H2B ubiquitination is proposed to be coupled to transcription. PAF1C is involved in mRNA 3' end formation probably through association with cleavage and poly(A) factors. In case of infection by influenza A strain H3N2, PAF1C associates with viral NS1 protein, thereby regulating gene transcription. Involved in polyadenylation of mRNA precursors. Connects PAF1C to Wnt signaling. . |
Accessions | Q8WVC0 ENST00000299601.10 [Q8WVC0-1] ENST00000315141.5 [Q8WVC0-2] |